Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Shattuck Labs SL-9258 /Anti-PD(L)1 Shows Broadened Anti-Tumor Activity In CPI-Resistant Cancers

  • Shattuck Labs Inc (NASDAQ:STTKannounced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including data from SL-9258 (TIGIT-Fc-LIGHT) and the Company's GADLEN platform.
  • Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC platform, demonstrates that SL-9258 simultaneously provides checkpoint blockade to all tumor-expressed PVR ligands and broadens immune costimulation. 
  • TIGIT-Fc-LIGHT was evaluated and well-tolerated in non-human primates at doses up to 40 mg/kg, and similar on-target pharmacodynamic activity was observed to what was characterized preclinically in mice.
  • Related: Takeda, Shattuck Labs Terminate Immuno-Oncology Pact.
  • Shattuck presented preclinical data highlighting the potential of GADLENs to direct gamma delta T cells to kill tumor cells.
  • Shattuck's bispecific GADLENs, targeting CD19 or CD20 tumor-antigens, demonstrated an ability to induce proliferation, degranulation, and cytokine production in Vg9Vd2+ T cells with costimulation of a natural cytotoxicity receptor or T cell costimulatory receptor. 
  • Further, CD19 and CD20 directed GADLENs enhanced the specific killing of lymphoma cells that express both antigen targets.
  • Price Action: STTK shares are down 2.79% at $3.83 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.